<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208766</url>
  </required_header>
  <id_info>
    <org_study_id>HOVON 95 MM</org_study_id>
    <secondary_id>2009-017903-28</secondary_id>
    <secondary_id>EMN02</secondary_id>
    <nct_id>NCT01208766</nct_id>
  </id_info>
  <brief_title>Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma</brief_title>
  <acronym>HO95</acronym>
  <official_title>A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stichting Hemato-Oncologie voor Volwassenen Nederland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Myeloma Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GIMEMA (Italian Group for Adult Hematologic Diseases)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DSMM (Deutsche Studiengruppe Multiples Myelom)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NMSG (Nordic Myeloma Study Group)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central European Myeloma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stichting Hemato-Oncologie voor Volwassenen Nederland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study phase: phase III

      Study objective:

        -  Comparison of Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed
           autologous stem cell transplantation (ASCT)

        -  Comparison of Bortezomib, Lenalidomide, Dexamethasone(VRD) as consolidation versus no
           consolidation

        -  Comparison of single versus tandem high dose Melphalan with ASCT

      Patient population: Patients with symptomatic multiple myeloma,previously untreated, ISS
      stages 1-3, age 18-65 years inclusive

      Study design: Prospective, multicenter, intergroup, randomized

      Duration of treatment: Expected duration of induction, stem cell collection and
      intensification is 6 - 9 months. Consolidation with VRD will last 2 months Maintenance
      therapy with Lenalidomide will be given until relapse. All patients will be followed until 10
      years after registration.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).</measure>
    <time_frame>end of trial (last patient last visit)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first</measure>
    <time_frame>end of trial (last patient last visit)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first</measure>
    <time_frame>end of trial (last patient last visit)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival measured from the time of registration /randomization R1/ randomization R2. Patients still alive or lost to follow up are censored at the date they were last known to be alive.</measure>
    <time_frame>end of trial (last patient last visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>End of trial (last patient last visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (PR, VGPR, CR and stringent CR), and improvement of response during the various stages of the treatment.</measure>
    <time_frame>end of trial (last patient last visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1: 1 (2) cycle(s) HDM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2: none</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No consolidation, patients will continue to Lenalidomide maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2: 2 cycles of VRD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib, Melphalan, Prednisone (VMP)</intervention_name>
    <description>Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32
Melphalan _ 9 mg/m² _ p.o. _ days 1-4
Prednisone _ 60 mg/m² _ p.o. _ days 1-4</description>
    <arm_group_label>R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 or 2 cycle(s) HDM (High Dose Melphalan)</intervention_name>
    <description>- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2*
*Patients with renal insufficiency 100 mg/m2 only at day -3
If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.</description>
    <arm_group_label>R1: 1 (2) cycle(s) HDM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)</intervention_name>
    <description>Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11
Lenalidomide _ 25 mg _ p.o. _ days 1-21
Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12</description>
    <arm_group_label>R2: 2 cycles of VRD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III
             according to the International Staging System ISS (see appendix A), i.e. at least one
             of the CRAB criteria should be present;

          -  Measurable disease as defined by the presence of M-protein in serum or urine (serum
             M-protein&gt; 10 g/l or urine M-protein &gt; 200 mg/24 hours), or abnormal free light chain
             ratio;

          -  Age 18-65 years inclusive;

          -  WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by
             comorbid conditions);

          -  Negative pregnancy test at inclusion if applicable;

          -  Written informed consent.

        Inclusion for randomisation 1:

          -  WHO performance 0-2;

          -  Bilirubin and transaminases &lt; 2.5 times the upper limit of normal values;

          -  A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according to
             national guidelines).

        Inclusion for randomisation 2:

          -  Bilirubin and transaminases &lt; 2.5 times the upper limit of normal values;

          -  ANC &gt;= 0.5 x 109/l and platelets &gt; 20 x 10^9/l;

          -  Patient is able to adhere to the requirements of the Lenalidomide Pregnancy Prevention
             Risk Management Plan.

        Exclusion Criteria:

          -  Known intolerance of Boron;

          -  Systemic AL amyloidosis;

          -  Primary Plasmacell Leukemia;

          -  Non-secretory MM;

          -  Previous chemotherapy or radiotherapy except local radiotherapy in case of local
             myeloma progression or corticosteroids maximum 5 days for symptom control;

          -  Severe cardiac dysfunction (NYHA classification II-IV);

          -  Significant hepatic dysfunction, unless related to myeloma;

          -  Patients with GFR &lt;15 ml/min,

          -  Patients known to be HIV-positive;

          -  Patients with active, uncontrolled infections;

          -  Patients with neuropathy, CTC grade 2 or higher;

          -  Patients with a history of active malignancy during the past 5 years with the
             exception of basal carcinoma of the skin or stage 0 cervical carcinoma;

          -  Patients who are not willing or capable to use adequate contraception during the
             therapy (all men, all pre-menopausal women);

          -  Lactating women.

        Exclusion for randomisation 1:

          -  Severe pulmonary, neurologic, or psychiatric disease;

          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment;

          -  Allogeneic Stem Cell Transplantation (Allo SCT) planned;

          -  Progressive disease.'

        Exclusion for randomisation 2:

          -  Progressive disease;

          -  Neuropathy, except CTCAE grade 1;

          -  CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Sonneveld, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stichting Hemato-Oncologie voor Volwassenen Nederland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.hovon.nl</url>
    <description>Hovon website</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma (Kahler's disease)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

